Sponsor or institution
Clinical trials and research at CRISPR Therapeutics
As of November 12, 2026, Find a Trial lists 5 clinical trials run by CRISPR Therapeutics that are recruiting, at sites in 6 countries (most in United States (5), Australia (3), Germany (2)). By phase: Phase 1/2 (3), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 6Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CTX340 in Adults with Uncontrolled Hypertension | Phase 1/2 | Port Orange, Florida and 1 other locations | Recruiting | Aug 11, 2026 |
| CTX112 (zugo-cel) for relapsed/refractory ITP and wAIHA in adults | Phase 1/2 | Boston, Massachusetts and 11 other locations | Recruiting | Apr 24, 2026 |
| CTX310 for refractory high triglycerides or LDL cholesterol | Phase 1 | Hialeah, Florida and 16 other locations | Recruiting | Mar 24, 2026 |
| Evaluating CTX112 for treating refractory autoimmune diseases in adults | Phase 1 | La Jolla, California and 16 other locations | Recruiting | Apr 13, 2025 |
| Evaluating CTX112 for B-cell malignancies | Phase 1/2 | Westwood, Kansas and 6 other locations | Recruiting | Dec 9, 2022 |
All recruiting trials (5)
-
CTX340 in Adults with Uncontrolled Hypertension
This study tests CTX340 versus placebo to see if it safely lowers blood pressure in adults with uncontrolled hypertension already on multiple meds.
-
CTX112 (zugo-cel) for relapsed/refractory ITP and wAIHA in adults
This trial tests CTX112, an off-the-shelf CD19 CAR-T therapy, to see if it can help adults with relapsed or refractory ITP or wAIHA.
-
CTX310 for refractory high triglycerides or LDL cholesterol
This trial will test whether a single IV dose of CTX310 is safe and tolerated in adults whose high triglycerides or LDL cholesterol have not responded to available treatments.
-
Evaluating CTX112 for treating refractory autoimmune diseases in adults
This study is testing a new CAR T cell treatment called CTX112 to see if it can help adults with tough autoimmune diseases like lupus and scleroderma feel better.
-
Evaluating CTX112 for B-cell malignancies
This study is testing a new type of CAR T cell therapy called CTX112 to see if it can safely help people with tough-to-treat B-cell cancers.
Quick answers
How many clinical trials run by CRISPR Therapeutics are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 6 countries. The most sites are in United States (5 trials), Australia (3 trials), Germany (2 trials), Spain (2 trials), New Zealand (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.